A Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor-positive, Her2-negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Trial Profile

A Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor-positive, Her2-negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Palbociclib (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Jun 2016 Trial phase has changed from phase III to phase IV and hence the planned patient no. has also be increased.
    • 21 Jun 2016 Planned number of patients changed from 150 to 300.
    • 01 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top